Previous studies have observed patients with blood-Tumor burden mutation (bTMB) ≥20 mut/Mb or high TMB regardless of PD-L1 expression significantly benefited from the PD-L1 plus CTLA-4 inhibitors in lung cancer3,4. This evidence concerns the gene CD274 and neoplasm.